O. Farokhzad

Molecular Biology · 2004–2017

A researcher in the Science corpus: 29 papers; trusts 23 researchers and is trusted by 23 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 343 citations into it; #2,972 of 17,773 by trust here, #1,002 by citations
• Biomaterials — 310 citations into it; #128 of 2,152 by trust here, #27 by citations
• Biomedical Engineering — 222 citations into it; #1,543 of 10,734 by trust here, #348 by citations
• Materials Chemistry — 132 citations into it
• Oncology — 74 citations into it
• Electronic, Optical and Magnetic Materials — 72 citations into it
• Cancer Research — 63 citations into it
• Cell Biology — 51 citations into it

Whom O. Farokhzad trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Mauro Ferrari
2. H. Maeda
3. Vladimir Torchilin
4. Rakesh K. Jain
5. F. Gu
6. Robert Langer
7. Mark E. Davis
8. George M. Whitesides
9. J. Swanson
10. R. Duncan

Who trusts O. Farokhzad overall

1. N. Bertrand
2. Liangfang Zhang
3. D. Ramimoghadam
4. N. Kamaly
5. Robert Langer
6. Héloïse Ragelle
7. Xiaoyang Xu
8. F. Gu
9. Alaaldin M. Alkilany
10. S. Mitragotri

Papers from O. Farokhzad's perspective

Ordered by how strongly the researchers O. Farokhzad trusts endorse each paper. Same corpus, a different order for every researcher.

1. Recent advances with liposomes as pharmaceutical carriers (Nature reviews. Drug discovery)
2. Polymer conjugates as anticancer nanomedicines (Nature Reviews. Cancer)
3. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. (Proceedings of the National Academy of Sciences of the United States of America)
4. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. (Progress in lipid research)
5. Nanoparticle therapeutics: an emerging treatment modality for cancer (Nature reviews. Drug discovery)
6. Nanoparticle-mediated cellular response is size-dependent. (Nature Nanotechnology)
7. Effect of pegylation on pharmaceuticals (Nature reviews. Drug discovery)
8. Delivering nanomedicine to solid tumors (Nature Reviews Clinical Oncology)
9. Role of extracellular matrix assembly in interstitial transport in solid tumors. (Cancer Research)
10. Understanding biophysicochemical interactions at the nano-bio interface. (Nature Materials)

Their papers

• Cytotoxicity and genotoxicity of silver nanoparticles in human cells. (2009) — 3,601 citations
• Nanocarriers as an emerging platform for cancer therapy. (2007) — 2,153 citations
• Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile (2012) — 1,110 citations
• Microfluidic platform for controlled synthesis of polymeric nanoparticles. (2008) — 827 citations
• Impact of nanotechnology on drug delivery. (2009) — 3,104 citations
• Nanoparticles in Medicine: Therapeutic Applications and Developments (2008) — 2,553 citations
• Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. (2006) — 1,672 citations
• Targeted polymeric therapeutic nanoparticles: design, development and clinical translation (2012) — 1,596 citations
• Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers (2008) — 715 citations
• Challenges and key considerations of the enhanced permeability and retention (EPR) effect for nanomedicine drug delivery in oncology (2013) — 1,264 citations
• Interactions of nanomaterials and biological systems: implications to personalized nanomedicine (2012) — 406 citations
• Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. (2007) — 916 citations
• Nanomedicine: developing smarter therapeutic and diagnostic modalities. (2006) — 772 citations
• Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles (2008) — 960 citations
• Nanoparticle delivery of cancer drugs. (2012) — 1,457 citations
• PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. (2009) — 683 citations
• Nanotechnology in drug delivery and tissue engineering: from discovery to applications. (2010) — 1,504 citations
• Nanoparticle-Aptamer Bioconjugates (2004) — 619 citations
• Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. (2008) — 969 citations
• Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014) — 2,587 citations